News Digging > Podcasts > Sliding vaccine sales, new costs, squeeze Moderna 4Q profit
Sliding vaccine sales, new costs, squeeze Moderna 4Q profit
Sliding vaccine sales, new costs, squeeze Moderna 4Q profit,Moderna’s fourth-quarter profit tumbled 70% as COVID-19 vaccine sales fell and the drugmaker caught up on a royalty payment. Heavy research and development costs also weighed on Moderna as the vaccine developer looks to strengthen an income statement currently dominated by its Spikevax coronavirus preventive shots.

Sliding vaccine sales, new costs, squeeze Moderna 4Q profit

Moderna’s fourth-quarter profit tumbled 70% as COVID-19 vaccine sales fell and the drugmaker caught up on a royalty payment. Heavy research and development costs also weighed on Moderna as the vaccine developer looks to strengthen an income statement currently dominated by its Spikevax coronavirus preventive shots.